Healthcare -
Biotechnology - NASDAQ - IE
$ 14.915
-0.765 %
$ 925 M
Market Cap
-18.88
P/E
1. INTRINSIC VALUE
Balance Sheet
GH Research PLC
| Current Assets | 154 M |
| Cash & Short-Term Investments | 149 M |
| Receivables | 150 K |
| Other Current Assets | 4.75 M |
| Non-Current Assets | 34 M |
| Long-Term Investments | 33.3 M |
| PP&E | 748 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 8.95 M |
| Accounts Payable | 3.74 M |
| Short-Term Debt | 255 K |
| Other Current Liabilities | 4.96 M |
| Non-Current Liabilities | 369 K |
| Long-Term Debt | 369 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
GH Research PLC
| Revenue | 0 |
| Cost Of Revenue | 315 K |
| Gross Profit | -315 K |
| Operating Expenses | 49.9 M |
| Operating Income | -50.2 M |
| Other Expenses | -11.3 M |
| Net Income | -39 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
GH Research PLC
| Net Income | -39 M |
| Depreciation & Amortization | 315 K |
| Capital Expenditures | -49 K |
| Stock-Based Compensation | 1.17 M |
| Change in Working Capital | 188 K |
| Others | -4.81 M |
| Free Cash Flow | -42.3 M |
Wall Street Analysts Price Targets
GH Research PLC
Wall Street analysts predict an average 1-year price target for GHRS of $28 , with forecasts ranging from
a
low of
$28 to a high of $28 .
GHRS Lowest Price Target
Wall Street Target
28 USD
87.73%
GHRS Average Price Target
Wall Street Target
28 USD
87.73%
GHRS Highest Price Target
Wall Street Target
28 USD
87.73%
4. DIVIDEND
ANALYSIS
GHRS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
GH Research PLC
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that, in June, it submitted its complete response to the previously announced clinical hold of its Investigational New Drug Application (IND) for GH001 to the U.S. Food and Drug Administration (FDA).
globenewswire.com
- 1 month ago
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting
DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Pharmaceutical Pipeline Presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) in Arizona, United States from May 27 – 30, where Professor Michael E. Thase, MD, Professor of Psychiatry, Perelman School of Medicine, University of Pennsylvania will present clinical data from a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001 in patients with treatment-resistant depression (TRD) (GH001-TRD-201).
globenewswire.com
- 2 months ago
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2025, and provided updates on its business.
globenewswire.com
- 2 months ago
What Makes GH Research (GHRS) a New Buy Stock
GH Research (GHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 2 months ago
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Full response to the IND hold on track for submission in mid-2025 Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024 Net cash proceeds of an additional $139.8 million from public offering received in February 2025 DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2024, and provided updates on its business. Business Updates GH001 in Patients with TRD GH001, our proprietary inhalable mebufotenin product candidate, is currently being investigated in a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial in approximately 80 patients with treatment-resistant depression (TRD) (GH001-TRD-201).
globenewswire.com
- 4 months ago
GHRS Stock Rallies 55% in a Week: Here's What You Should Know
GH Research stock soars 55% in a week after the company meets the primary goal in a mid-stage depression study of its lead candidate, GH001.
zacks.com
- 5 months ago
GH Research Announces Pricing of $150 Million Public Offering
DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of its previously announced underwritten public offering in the United States of 10,000,000 ordinary shares at a public offering price of $15.00 per share for total gross proceeds of approximately $150 million. All of the ordinary shares are being offered by GH Research PLC. The offering is expected to close on February 6, 2025, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 ordinary shares at the public offering price, less underwriting discounts and commissions.
globenewswire.com
- 5 months ago
GH Research Announces Proposed Public Offering
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the commencement of an underwritten public offering in the United States of $150 million of ordinary shares. All of the ordinary shares are to be offered by GH Research PLC. In addition, GH Research PLC intends to grant the underwriters an option to purchase up to an additional $22.5 million of ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
globenewswire.com
- 5 months ago
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company, today reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression (TRD) (GH001-TRD-201). GH Research will host a conference call and live webcast today at 8.00 a.m. EST. To register for the event, please click here.
globenewswire.com
- 5 months ago
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD).
globenewswire.com
- 5 months ago
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
DUBLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates on its business and highlighted key upcoming milestones.
globenewswire.com
- 6 months ago
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?
The mean of analysts' price targets for GH Research (GHRS) points to a 225.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
zacks.com
- 7 months ago
8. Profile
Summary
GH Research PLC GHRS
COUNTRY
IE
INDUSTRY
Biotechnology
MARKET CAP
$ 925 M
Dividend Yield
0.00%
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Contact
28 Baggot Street Lower, Dublin, D02 NX43
https://www.ghres.com
IPO
Date
June 25, 2021
Employees
50
Officers
Ms. Julie Ryan F.C.A.
Vice President of Finance
Mr. Florian Schonharting M.Sc. (Econ)
Co-Founder & Non-Executive Chairman of the Board
Mr. Aaron Cameron M.B.A.
Chief Operating Officer
Mr. Magnus Halle
Co-Founder & MD of Ireland
Dr. Velichka Valcheva M.D., M.Sc.
Chief Executive Officer